![Noah Beerman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Noah Beerman
Amministratore Delegato presso AI Proteins, Inc.
Posizioni attive di Noah Beerman
Società | Posizione | Inizio | Fine |
---|---|---|---|
AI Proteins, Inc.
![]() AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Direttore/Membro del Consiglio | 01/04/2023 | - |
Amministratore Delegato | 08/08/2023 | - | |
Direttore operativo | 01/04/2023 | 08/08/2023 |
Storia della carriera di Noah Beerman
Precedenti posizioni note di Noah Beerman
Società | Posizione | Inizio | Fine |
---|---|---|---|
FORTRESS BIOTECH, INC. | Direttore operativo | 26/09/2011 | 05/11/2013 |
Contatto Relazioni con gli Investitori | 26/09/2011 | 05/11/2013 | |
Public Communications Contact | 26/09/2011 | 05/11/2013 | |
Galena Biopharma, Inc.
![]() Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Direttore/Membro del Consiglio | 05/11/2009 | 31/03/2011 |
Amministratore Delegato | 05/11/2009 | 31/03/2011 | |
Presidente | 05/11/2009 | 31/03/2011 | |
Indevus Pharmaceuticals, Inc.
![]() Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01/06/1997 | 25/03/2009 |
Trasir Therapeutics, Inc.
![]() Trasir Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Altamira Therapeutics Ltd., Trasir Therapeutics, Inc. develops specialty pharmaceutical products. The company is based in Tampa, FL. The company was founded by Samuel A. Wickline. Trasir Therapeutics was acquired by Altamira Therapeutics Ltd. on June 03, 2021 for $4.32 million. | Direttore/Membro del Consiglio | 01/01/2015 | - |
POXEL | Corporate Officer/Principal | 01/01/2015 | - |
Technology Management & Funding LP | Corporate Officer/Principal | - | - |
Formazione di Noah Beerman
Rochester Christian University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Francia | 2 |
Posizioni
Corporate Officer/Principal | 3 |
Director/Board Member | 3 |
Chief Executive Officer | 2 |
Settori
Health Technology | 7 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
FORTRESS BIOTECH, INC. | Health Technology |
POXEL | Health Technology |
Aziende private | 5 |
---|---|
Indevus Pharmaceuticals, Inc.
![]() Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
Technology Management & Funding LP | |
Galena Biopharma, Inc.
![]() Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Health Technology |
Trasir Therapeutics, Inc.
![]() Trasir Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Altamira Therapeutics Ltd., Trasir Therapeutics, Inc. develops specialty pharmaceutical products. The company is based in Tampa, FL. The company was founded by Samuel A. Wickline. Trasir Therapeutics was acquired by Altamira Therapeutics Ltd. on June 03, 2021 for $4.32 million. | Health Technology |
AI Proteins, Inc.
![]() AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Health Technology |
- Borsa valori
- Insiders
- Noah Beerman
- Esperienza